Absynth develops innovative vaccines to prevent bacterial infections to address the challenge of antimicrobial resistance
Full website coming soon!
Prevention of infections directly reduces the need for antibiotics and prophylactic vaccines have never induced resistance. Absynth’s vaccines target Staphylococcus aureus and Clostridium difficile, the cause of damage to health or death. Absynth is competitively placed with a suite of novel protein vaccine antigens that differ from and offer possible benefits over competitor products.
Dr Fiona Marston, Chief Executive
Absynth Biologics is led by experienced management, scientists and advisors, with strong track records.